Targeting a majority of patients with T2DM, these studies consistently showed that early treatment with SGLT2 inhibitors following an AMI favorably impacts CV and mortality outcomes, reinforcing the hypothesis that T2DM is a key factor in achieving the therapeutic benefit. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.